Oxaliplatin Hikma

Oxaliplatin, the active ingredient in Oxaliplatin Hikma, is a platinum‑based chemotherapy agent presented as a sterile solution for intravenous use. It is employed in the treatment of colorectal cancer, often in combination with other chemotherapeutic agents, and is administered to adult patients. GNH USA supplies Oxaliplatin Hikma as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres, hospitals and pharmacies worldwide.

GNH USA supplies Oxaliplatin Hikma as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres, hospitals and pharmacies worldwide.

Oxaliplatin is used in colorectal cancer treatment protocols that target the DNA replication pathway.

- Colorectal cancer: Enhances tumor response when combined with fluoropyrimidines and leucovorin. - Gastric cancer: Used in combination regimens for advanced disease. - Pancreatic cancer: Part of multi‑drug protocols for metastatic disease.

Oxaliplatin may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Nausea and vomiting: Frequently reported during or after infusion. - Peripheral neuropathy: Tingling or numbness, often dose‑dependent. - Diarrhea: May occur during treatment cycles. - Fatigue: Generalised tiredness reported by many patients. - Thrombocytopenia: Reduced platelet counts observed in blood tests.

Serious or Rare Side Effects: - Severe hypersensitivity reactions: Including anaphylaxis, requiring immediate medical attention. - Acute hemolytic anemia: Rare but potentially life‑threatening. - Pulmonary toxicity: Interstitial lung disease or pneumonitis. - Cardiac arrhythmias: Uncommon electro‑cardiographic changes. - Renal impairment: Acute kidney injury in susceptible individuals.

When using Oxaliplatin, clinicians should observe several safety measures.

- Renal function monitoring: Assess baseline creatinine and adjust as needed. - Neuropathy assessment: Conduct regular neurological examinations. - Hematologic monitoring: Check complete blood counts before each cycle. - Hypersensitivity preparedness: Have emergency medications available during infusion. - Pregnancy and lactation: Avoid use unless benefits outweigh risks. - Store at ambient temperature: Keep in original packaging, protect from light and moisture.

Oxaliplatin can interact with several concomitant medications, requiring careful management.

Major Interactions (Avoid): - Nephrotoxic agents: Concurrent use with aminoglycosides may increase kidney injury risk. - Anticoagulants: Heightened bleeding risk when combined with warfarin or direct oral anticoagulants.

Moderate Interactions (Monitor Closely): - Antiemetics: Certain serotonin‑receptor antagonists may alter oxaliplatin clearance. - CYP450 inducers: May reduce plasma concentrations of oxylatin. - Radiotherapy: Combined modality may increase neurotoxicity. - Herbal supplements: St. St   ---